Applications of 2,3-O-Isopropylidene-D-Ribofuranoside in Industrial Manufacturing

2,3-O-Isopropylidene-D-Ribofuranoside serves as a key intermediate in several advanced manufacturing sectors where selective protection of ribose sugars is essential. As the direct manufacturer, we supply this material to established industry clients for critical syntheses where stringent batch traceability and compliance are required.

1. Nucleoside Pharmaceutical Synthesis

This compound plays a direct role in the synthesis of antiviral and anticancer nucleoside analogs, where regulated sugar protection ensures structural accuracy of active pharmaceutical ingredients. Pharmaceutical companies include it in early stage synthesis for drugs like cytarabine, vidarabine, and other ribofuranosyl derivatives requiring acetonide protection. The reliability of stereochemistry is crucial for API quality and regulatory approvals.

Industry compliance standards

• USP, EP, and JP pharmacopeias for nucleoside APIs
• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• FDA 21 CFR Part 211 for finished pharmaceuticals
• ISO 9001:2015 certified quality system for excipient and intermediate materials

Typical usage ratio

• Commonly 1.05–1.15 molar equivalents relative to ribose substrates
• Adjustment depends on purity and desired yield at each stage
• Reaction conducted under controlled anhydrous conditions
• Excess minimized to reduce downstream purification load

Downstream process integration

• Used in initial step for protection of ribose hydroxyl groups
• Introduced before subsequent functionalization (e.g., halogenation, amination)
• Deprotection carried out after nucleobase introduction using mild acid hydrolysis
• Subject to in-process QC to confirm complete conversion and low by-products

Final product types

• API-grade nucleoside drugs (e.g., cytarabine, vidarabine, fludarabine)
• Research-grade nucleoside building blocks
• Intermediates for antiviral pharmaceuticals
• Custom nucleotide analogs under GMP

2. Diagnostic Oligonucleotide Manufacturing

Leading biotechnology companies rely on this protected sugar derivative as a raw material for oligonucleotide and probe synthesis. Strict batch reproducibility is necessary for consistency in automated phosphoramidite synthesis platforms. Its reliable purity profile supports the production of primers, probes, and antisense molecules intended for FDA-cleared in vitro diagnostics.

Industry compliance standards

• ISO 13485 for medical device and diagnostics quality systems
• FDA 21 CFR Part 820 for IVD manufacturing
• CLSI protocols for oligonucleotide consistency
• Suppliers must provide BSE/TSE statements and validated residual solvent data

Typical usage ratio

• 0.9–1.1 molar equivalents relative to nucleoside or sugar starting material
• Precisely weighed to accommodate automated synthesis requirements
• Concentration adjusted by platform throughput and batch size
• Further purification steps applied to achieve instrument-ready purity

Downstream process integration

• Protection of sugar moiety before conjugation to phosphorus group
• Stabilizes intermediates during solid-phase or solution synthesis steps
• Deprotection performed before labeling or terminal modification
• Residual acetonide removal verified by HPLC and NMR analysis

Final product types

• Custom oligonucleotides for PCR, qPCR, and LAMP assays
• RNA/DNA hybrid probes for diagnostic test kits
• Antisense oligomers for molecular diagnostics
• Fluorescently-labeled detection probes

3. Enzyme Substrate & Cofactor Synthesis

Enzyme manufacturers and biochemical reagent producers use this intermediate for the controlled synthesis of ribose-based enzyme substrates and cofactors. High-purity acetonide protection enables selective modifications for research enzymes and diagnostic assay reagents, where interference from unprotected hydroxyl groups must be avoided to maintain enzyme specificity metrics.

Industry compliance standards

• ISO 9001:2015 for laboratory reagents
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals
• OECD Principles of Good Laboratory Practice for QC lots
• Safety Data Sheet compliance to GHS (Globally Harmonized System)

Typical usage ratio

• 1:1 to 1.2:1 molar ratio depending on ribose or nucleoside substrate
• Adjusted based on target substitution efficiency and scale
• Applied under inert gas to minimize oxidation
• Material recovery steps established for high-volume synthesis

Downstream process integration

• Protection of ribose prior to selective activation or phosphorylation
• Used in route to prepare 5-phosphorylated or adenosine-conjugated cofactors
• Support cleavage and purification before use in assay formulation
• Lot qualification tested by enzyme kinetics and NMR confirmation

Final product types

• NAD/NADP coenzyme analogs
• ATP and GTP ribose-labeled enzyme substrates
• Labeled ribosyl donors for bioassays
• Buffer additives for diagnostic enzyme formulations

4. Fine Chemical Building Block for Carbohydrate Chemistry

Producers of advanced carbohydrate derivatives use this compound for the synthesis of custom glycosides, carbohydrate antigens, and glycosylated intermediates. Its acetonide-protected structure ensures regioselectivity during stepwise synthesis required in carbohydrate chemistry, reducing risks from by-product formation and cross-reactivity during large-scale operations for specialty chemicals or pharmaceutical adjuvants.

Industry compliance standards

• ISO 9001:2015 process controls for specialty chemical synthesis
• REACH (EC 1907/2006) registration for downstream applications in Europe
• FDA 21 CFR 173 for indirect food additive contact, if applied in food-related adjuvant processes
• Traceability for all starting materials according to EFSA food safety policy (where applicable)

Typical usage ratio

• 1.0–1.3 molar ratio depending on desired glycosylation pattern
• Increment fine-tuned based on scale-up and downstream substitution steps
• Monitoring required for highly functionalized targets
• Used with molecular sieves and mild acid catalysts

Downstream process integration

• Protection prior to glycosyl donor or acceptor preparation
• Key intermediate for stepwise oligosaccharide synthesis
• Acetonide group removed selectively without disturbing base sugar structure
• Site-specific functionalization achieved before advanced coupling

Final product types

• Synthetic oligosaccharides
• Glycosylated pharmaceutical intermediates
• Immune adjuvant carbohydrate derivatives
• Carbohydrate-based specialty chemicals